ABBV to Buy APGE
AbbVie is closing in on a nearly $11 billion deal to buy Apogee Therapeutics
APGE ABBV AbbVie Close to Nearly $11B Deal to Buy Apogee Therapeutics: FT (Bloomberg) -- AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics, the Financial Times reports, citing poeple familiar with the matter. •Under the terms being discussed, AbbVie would pay Apogee shareholders $10.9 billion in cash •Deal expected to be announced as soon as Monday •AbbVie and Apogee did not immediately respond to the FT's requests for comment